Columbia University

Technology Ventures

JLABS Presents: Meet with... Canaan Partners

June 27, 2017
Speaker: 
Colleen Cuffaro | Principal, Canaan Partners
New York Genome Center
101 6th Ave, 1st Floor
New York, NY
10013
10:30am

Overview:

Canaan Partners is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $4.2 billion under management, a diversified fund and 190 exits to date, Canaan has funded some of the world's leading technology companies including LendingClub, Ebates, PrimeSense, and Skybox Imaging as well as healthcare stars like Chimerix, Durata, Labrys Biologics, Novira, CytomX and Civitas Therapeutics. Canaan is currently investing in a $675 million fund focused on early stage IT and healthcare startups. The fund's healthcare focus includes early stage biopharma, medical devices, and digital health. 

Colleen Cuffaro will be in attendance on June 27th to provide an overview presentation of Canaan's areas of interest and best practices when applying for funding. Colleen will be on hand to meet with a handful of applicants one-on-one after the presentation. 

Agenda:

10:30 AM | Registration Opens and Networking
11:00 AM | Presentation and Q&A 
11:45 AM | Networking Lunch 
1:00-5:00 PM | One-on-one Meetings* 

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on June 1st. 

Fees:

Presentation & Lunch
$ 25 | General Public
$ 35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on June 26th (or sold out). 

One-on-One Meeting
FREE | Application
FREE | Accepted Companies 
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on June 1st. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.